Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer

Current Cancer Drug Targets

Volumn 14, Issue 4, 2014, Pages 348-356

  Li, Wei ^a   Wu, Zheng ^a   Ma, Qingyong ^a   Liu, Jiangbo ^a   Xu, Qinhong ^a   Han, Liang ^a   Duan, Wanxing ^a   Lv, Yunfu ^b   Wang, Fengfei ^c   Reindl, Katie M ^c   Wu, Erxi ^c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Glucose; MAPK pathway; Pancreatic cancer; ROS; TXNIP

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN; TXN PROTEIN, HUMAN; TXNIP PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PHOSPHORYLATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; DIABETES MELLITUS; DRUG EFFECTS; FEMALE; GENE SILENCING; GENETICS; MALE; METABOLISM; OXIDATIVE STRESS; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CARRIER PROTEINS; CELL LINE, TUMOR; DIABETES MELLITUS; FEMALE; GENE SILENCING; HUMANS; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; OXIDATIVE STRESS; PANCREAS; PANCREATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; THIOREDOXINS; UP-REGULATION;

EID: 84903726507     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140331231658     Document Type: Article

References (33)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Sarkar, F. H.; Banerjee, S.; Li, Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol. Appl. Pharmacol. 2007, 224, 326-336.
3. Zhou, J.; Du, Y. Acquisition of resistance of pancreatic cancer cells to 2-methoxyestradiol is associated with the upregulation of manganese superoxide dismutase. Mol. Cancer Res. 2012, 10, 768-777.
4. Cui, Y.; Andersen, D. K. Diabetes and pancreatic cancer. Endocr. Relat. Cancer 2012, 19, F9-F26.
5. Giovannucci, E.; Michaud, D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132, 2208-2225.
6. Pannala, R.; Basu, A.; Petersen, G. M.; Chari, S. T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10, 88-95.
7. Li, W.; Ma, Q.; Li, J.; Guo, K.; Liu, H.; Han, L.; Ma, G. Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide. Oncol. Rep. 2011, 25, 1279-1287.
8. Nishikawa, M.; Hashida, M.; Takakura, Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv. Drug Deliv. Rev. 2009, 61, 319-326.
9. Kolarova, H.; Nevrelova, P.; Tomankova, K.; Kolar, P.; Bajgar, R.; Mosinger, J. Production of reactive oxygen species after photodynamic therapy by porphyrin sensitizers. Gen. Physiol. Biophys. 2008, 27, 101-105.
10. Ray, P. D.; Huang, B. W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012, 24, 981-990.
11. Yamawaki, H.; Berk, B. C. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr. Opin. Nephrol. Hypertens. 2005, 14, 149-153.
12. Turturro, F.; Friday, E.; Welbourne, T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxininteracting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 2007, 7, 96.
13. Ren, Y.; Shi, Y.; Wang, Y.; Li, Y.; Wu, S.; Li, H.; Zhang, Y.; Duan, H. p38 MAPK pathway is involved in high glucose-induced thioredoxin interacting protein induction in mouse mesangial cells. FEBS Lett. 2010, 584, 3480-3485.
14. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25, 402-408.
15. Cartwright, T.; Richards, D. A.; Boehm, K. A. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control. 2008, 15, 308-313.
16. Reuter, S.; Gupta, S. C.; Chaturvedi, M. M.; Aggarwal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 2010, 49, 1603-1616.
17. Han, L.; Ma, Q.; Li, J.; Liu, H.; Li, W.; Ma, G.; Xu, Q.; Zhou, S.; Wu, E. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One 2011, 6, e27074.
18. Li, J.; Ma, Q.; Liu, H.; Guo, K.; Li, F.; Li, W.; Han, L.; Wang, F.; Wu, E. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One 2011, 6, e17385.
19. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813-820.
20. Baker, A. F.; Koh, M. Y.; Williams, R. R.; James, B.; Wang, H.; Tate, W. R.; Gallegos, A.; Von Hoff, D. D.; Han, H.; Powis, G. Identification of thioredoxin-interacting protein 1 as a hypoxiainducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 2008, 36, 178-186.
21. Chen, Z.; Lopez-Ramos, D. A.; Yoshihara, E.; Maeda, Y.; Masutani, H.; Sugie, K.; Maeda, M.; Yodoi, J. Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation. Leukemia 2011, 25, 440-448.
22. Han, S. H.; Jeon, J. H.; Ju, H. R.; Jung, U.; Kim, K. Y.; Yoo, H. S.; Lee, Y. H.; Song, K. S.; Hwang, H. M.; Na, Y. S.; Yang, Y.; Lee, K. N.; Choi, I. VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cellcycle progression. Oncogene 2003, 22, 4035-4046.
23. Chen, J.; Saxena, G.; Mungrue, I. N.; Lusis, A. J.; Shalev, A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008, 57, 938-944.
24. Chutkow, W. A.; Patwari, P.; Yoshioka, J.; Lee, R. T. Thioredoxininteracting protein (Txnip) is a critical regulator of hepatic glucose production. J. Biol. Chem. 2008, 283, 2397-2406.
25. Zhou, J.; Chng, W. J. Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. Mitochondrion 2013, 13, 163-169.
26. Turturro, F.; Von Burton, G.; Friday, E. Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancerderived cells and regulates paclitaxel IC50. Clin. Cancer Res. 2007, 13, 3724-3730.
27. Cates, J. M.; Byrd, R. H.; Fohn, L. E.; Tatsas, A. D.; Washington, M. K.; Black, C. C. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas. 2009, 38, e1-6.
28. Wei, J.; Shi, Y.; Hou, Y.; Ren, Y.; Du, C.; Zhang, L.; Li, Y. Ameliorates high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Cell Signal. 2013, 25, 2788-2796.
29. Li, W.; Ma, Q.; Liu, J.; Han, L.; Ma, G.; Liu, H.; Shan, T.; Xie, K.; Wu, E. Hyperglycemia as a mechanism of pancreatic cancer metastasis. Front. Biosci. 2012, 17, 1761-1774.
30. Acharya, A.; Das, I.; Chandhok, D.; Saha, T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell Longev. 2010, 3, 23-34.
31. McCubrey, J. A.; Lahair, M. M.; Franklin, R. A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 2006, 8, 1775-1789.
32. Cheng, J. C.; Klausen, C.; Leung, P. C. Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol. Endocrinol. 2010, 24, 1569-1580.
33. Lee, K. H.; Kim, J. R. Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor. Exp. Mol. Med. 2009, 41, 180-188.